{
    "organizations": [],
    "uuid": "7b38d160552928bc9d10ead206bcc2d98f40054f",
    "author": "",
    "url": "https://www.reuters.com/article/brief-eloxx-pharmaceuticals-announces-or/brief-eloxx-pharmaceuticals-announces-orphan-drug-designation-for-elx-02-for-treatment-of-cystinosis-idUSASC09Y2M",
    "ord_in_thread": 0,
    "title": "BRIEF-Eloxx Pharmaceuticals Announces Orphan-Drug Designation For ELX-02 For Treatment Of Cystinosis",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 27, 2018 / 4:42 PM / Updated 16 minutes ago BRIEF-Eloxx Pharmaceuticals Announces Orphan-Drug Designation For ELX-02 For Treatment Of Cystinosis Reuters Staff 1 Min Read\nApril 27 (Reuters) - Eloxx Pharmaceuticals Inc:\n* ELOXX PHARMACEUTICALS ANNOUNCES FDA GRANT OF ORPHAN-DRUG DESIGNATION FOR INVESTIGATIONAL DRUG ELX-02 FOR TREATMENT OF CYSTINOSIS Source text for Eikon: Further company coverage:",
    "published": "2018-04-27T19:42:00.000+03:00",
    "crawled": "2018-04-27T20:04:00.032+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "pm",
        "updated",
        "minute",
        "ago",
        "pharmaceutical",
        "announces",
        "designation",
        "treatment",
        "cystinosis",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "eloxx",
        "pharmaceutical",
        "inc",
        "eloxx",
        "pharmaceutical",
        "announces",
        "fda",
        "grant",
        "designation",
        "investigational",
        "drug",
        "treatment",
        "cystinosis",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}